IL-27 confers a protumorigenic activity of regulatory T cells via CD39.
Young-Jun ParkHeeju RyuGaram ChoiByung-Seok KimEun Sook HwangHun Sik KimYeonseok ChungPublished in: Proceedings of the National Academy of Sciences of the United States of America (2019)
Expression of ectonucleotidase CD39 contributes to the suppressive activity of Foxp3+ regulatory T cells (Tregs) by hydrolyzing immunogenic ATP into AMP. The molecular mechanism that drives CD39 expression on Tregs remains elusive. We found that tumor-infiltrating Tregs (Ti-Tregs) failed to up-regulate CD39 in mice lacking EBI3 subunit of IL-27 or IL-27Ra. Mixed bone marrow chimera and in vitro studies showed that IL-27 signaling in Tregs directly drives CD39 expression on Ti-Tregs in a STAT1-dependent, but STAT3- and T-bet-independent, manner. Tregs stimulated with IL-27 showed enhanced suppressive activities against CD8+ T cell responses in vitro. Moreover, IL-27Ra-deficient Tregs and STAT1-deficient Tregs were less efficient than WT Tregs in suppressing antitumor immunity in vivo. CD39 inhibition significantly abolished IL-27-induced suppressive activities of Tregs. Thus, IL-27 signaling in Tregs critically contributes to protumorigenic properties of Tregs via up-regulation of CD39.
Keyphrases
- regulatory t cells
- bone marrow
- poor prognosis
- dendritic cells
- rheumatoid arthritis
- cell proliferation
- nk cells
- metabolic syndrome
- signaling pathway
- mesenchymal stem cells
- binding protein
- endothelial cells
- immune response
- insulin resistance
- systemic lupus erythematosus
- high glucose
- ankylosing spondylitis
- wild type
- high fat diet induced
- case control